Skip to main navigation Skip to search Skip to main content

Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors

  • Natalia Moreno
  • , Till Holsten
  • , Julius Mertins
  • , Annabelle Zhogbi
  • , Pascal Johann
  • , Marcel Kool
  • , Michael Meisterernst
  • , Kornelius Kerl

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)

Abstract

Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcription machinery is a promising option for preventing exaggerated tumor cell proliferation and survival as it may bypass compensatory mechanisms. In support of this hypothesis, we report efficient impairment of cellular proliferation and strong induction of cell death elicited by inhibition of bromodomain protein BRD4 and transcription kinase CDK9 using small molecular compounds. Combination of both compounds efficiently represses antiapoptotic genes and the oncogene MYC. Our results provide a novel approach for the treatment of RT.

Original languageEnglish
Pages (from-to)84986-84995
Number of pages10
JournalOncotarget
Volume8
Issue number49
DOIs
Publication statusPublished - 17 Oct 2017
Externally publishedYes

Keywords

  • BRD4
  • CDK9
  • Rhabdoid tumors
  • SMARCB1
  • Synergistic

Fingerprint

Dive into the research topics of 'Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors'. Together they form a unique fingerprint.

Cite this